stockrowPerrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Revenue
- −5.24%
- EPS
- −494.6%
- Free cash flow
- +138.5%
- Total debt
- −9.62%
Quarter to September 2026, against a year earlier
Follow PRGO
Alert me
Perrigo Company plc (PRGO) EBITDA
Perrigo Company plc's EBITDA for fiscal 2025 was −$775.7M, compared with $447.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.2B. Over the past ten years it has ranged from −$1.6B (fiscal 2016) to $1.0B (fiscal 2017); the current reading is higher than 17% of that period. Perrigo Company plc ranks 79th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$775.7M | — |
| FY2024 | $447.7M | (12.85%) |
| FY2023 | $513.7M | 23.25% |
| FY2022 | $416.8M | (42.01%) |
| FY2021 | $718.8M | 10.99% |
| FY2020 | $647.6M | 14.26% |
| FY2019 | $566.8M | (13.07%) |
| FY2018 | $652.0M | (36.12%) |
| FY2017 | $1.0B | — |
| FY2016 | −$1.6B | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $121.3M | — |
| Mar 2026 | −$286.8M | — |
| Dec 2025 | −$1.2B | — |
| Sep 2025 | $160.3M | 19.72% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | $330.9M |
| ANIP ANI Pharmaceuticals, Inc. compare | $236.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $52.9M |
| RGC Regencell Bioscience Holdings Limited compare | −$12.5M |
| ALVO Alvotech compare | −$84.5M |
| TRLV Trulieve Cannabis Corp. compare | −$104.9M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$313.5M |
| PRGO Perrigo Company plc | −$1.2B |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$3.3B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on PRGO
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement